The most powerful therapeutic antibodies exist, but are too toxic to use. We're changing that.

01 - The Problem

T-cell immunotherapy works. But it can kill the patient it's meant to save.

The therapies capable of destroying solid tumours are so potent that, released into the bloodstream, they trigger catastrophic systemic toxicity - cytokine release, organ failure, death. The science is not the obstacle. Control is.

~100

clinical trials of T-cell engaging therapies for solid tumours

0

approved therapies for solid tumours to date

02 - Our Solution

Cloaked Antibody Activation

CAA keeps a therapeutic antibody inert as it travels through the body, then switches it on only inside the tumour. Full potency, zero collateral.

01

Cloak

The antibody's active site is masked, rendering it therapeutically silent in circulation - no binding, no toxicity.

02

Deliver

The cloaked antibody circulates safely and accumulates at the tumour, guided to the site where treatment is needed.

03

Activate

A tumour-localised trigger uncloaks the antibody in situ, unleashing full therapeutic potency precisely where it matters.

03 - Leadership

Deep expertise, from bench to clinic.

Prof. Colin Self

Prof. Colin Self

Strategic Advisor

Originator of the cloaking chemistry underpinning the platform.

Dr Jonathan Harburn

Dr Jonathan Harburn

Chief Technology Officer

Leads molecular design and platform engineering.

Johannes Hesford

Johannes Hesford

Chief Operating Officer

Drives operations, strategy and corporate development.

Jason Gill

Dr Jason Gill

Clinical Advisor

Toxicology expert in cancer therapeutics. Steers clinical study design and safety.

Declan Cunningham

Declan Cunningham

Head of Finance

Former EY tax partner, and life science spin-out specialist.

We're looking to expand our team as we progress through in‑vitro and in‑vivo to clinical stage. If you're interested in being involved, please message us at careers@precisionitx.com.

04 - Latest news

Three decades of peer-reviewed groundwork underpin the platform. Keep an eye out for upcoming papers.

Contact us

Press enquiries: hello@precisionitx.com

Investor relations: ir@precisionitx.com


Connect with us on LinkedIn.